Developer docs
API playgroundTry for free, no card

Search company profiles

MeVis Medical Solutions AG

Full company profile

uuid0038lax

Namestring
MeVis Medical Solutions AG
Legal namestring
MeVis Medical Solutions AG
Websiteurl
mevis.de
Company typeenum
Public
Founded yearint
1997
Descriptiontext

MeVis Medical Solutions AG is a Bremen, Germany-based, publicly traded (Frankfurt/XETRA, Berlin, Düsseldorf, Munich, Stuttgart; ticker M3V; ISIN DE000A0LBFE4) developer of image-based medical diagnostic software, founded in 1997 with technical roots in the 1992 CeVis initiative at the University of Bremen and the German Cancer Research Center (DKFZ). It has been listed since 2007 and is majority-owned by Varex Imaging Corporation (USA) through Varex Imaging Deutschland AG, with a control and profit transfer agreement in place subordinating the listing to the parent group. The company focuses on image-based early detection and diagnosis of breast, lung, and liver cancer as well as neurological diseases, supporting all major imaging modalities (MRI, digital mammography, CT, tomosynthesis, and ultrasound).

The product portfolio is built around the MeVisLab development platform and the MeVisAP application development platform. Application-layer products include Veolity (AI-powered lung cancer screening workflow for radiologists and national screening programs), MeVis Liver Suite (liver disease analysis), MeVis Online Academy (radiologist education via webinars and case collections), and MeVis Distant Services (MDS, remote support). The company operates an EN ISO 13485:2016-certified quality management system across EU, USA, Canada, Australia, and Taiwan under MDR, MDSAP, and related regimes.

Revenue is generated primarily through software licensing, development services, and ongoing support/maintenance sold via direct enterprise sales to medical device manufacturers and medical IT platform providers (RIS/PACS), with end users including radiologists and clinical institutions. Reported FY2024/2025 revenue was €16,061k against ~102 FTE, with an EBIT margin of 13% — down from €16,972k and 21% in FY2023/2024 — and a May 2026 forecast adjustment signaled continued near-term pressure. Marketing channels combine major industry congresses (RSNA, ECR, ESTI, RÖKO, ILTS, WCLC), the MeVis Online Academy, the corporate website, and LinkedIn/XING.

Short descriptiontext

MeVis Medical Solutions AG is a Bremen-based, publicly traded medical imaging software company majority-owned by Varex Imaging Corporation, developing AI-assisted diagnostic software (Veolity lung cancer screening, MeVis Liver Suite, MeVisLab platform) licensed to medical device manufacturers and healthcare IT platform providers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBremen, Germany
HQ citystring
Bremen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging software, lung cancer screening, liver diagnostics software, radiology software solutions, clinical image analysis
Industry1 code
1AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
CodeHLACALAGPrimaryYes
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Custom Computer Programming Services541511
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Medical Imaging Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Software Licenses and Applications
TypeSubscription Recurring
Description

MeVis develops and markets innovative software for analysis and evaluation of medical image data to manufacturers of medical products and providers of medical IT platforms. Revenue is generated through software licensing, development services, and ongoing support/maintenance.

mevis.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1MeVisLab
Description

Software platform for medical image processing and visualization.

mevis.de
+5 more records
Core offering1 text field

MeVis Medical Solutions AG develops and markets specialized software for the analysis and evaluation of medical image data, supporting image-based early detection and diagnosis of breast, lung, and liver cancer as well as neurological diseases. The company sells its software products (including Veolity lung cancer screening, MeVis Liver Suite, and the MeVisLab platform) to manufacturers of medical devices and providers of medical IT platforms, with full-service support from product concept and application development through integration into customer platforms and ongoing quality assurance.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

MeVis Medical Solutions AG offers a portfolio of medical imaging software solutions comprising its core products Veolity (lung cancer screening with AI), MeVis Liver Suite (liver diagnostics), and MeVisLab (development platform). These are complemented by professional services including MeVis Online Academy (radiology education via webinars and case collections) and MeVis Distant Services (remote support). The company focuses on image-based early detection and diagnosis of epidemiologically significant diseases including breast cancer, lung cancer, liver cancer, and neurological diseases, supporting all major imaging modalities (MRI, digital mammography, CT, tomosynthesis, and ultrasound).

Product and service6 records
1Veolity
CategoryLung cancer screening software
Description

Comprehensive lung cancer screening software solution that supports radiologists, screening centers, and national screening initiatives at every stage of the diagnostic workflow using AI-powered analysis for lung nodule management.

2MeVis Liver Suite
CategoryLiver diagnostics software
Description

Specialized software suite for liver disease diagnosis and analysis that supports surgeons and medical professionals in liver-related imaging workflows.

3MeVisLab
CategoryMedical image processing platform
Description

Proprietary development environment and technical competence platform providing tools for visualizing and processing imaging data from medical to industrial applications, including a Path Tracer for photorealistic renderings.

4MeVis Online Academy
CategoryRadiology professional education
Description

Webinar and case collection platform for radiologists offering educational content and professional development resources, including COVID-19 case collections.

5MeVis Distant Services (MDS)
CategoryRemote support services
Description

Remote professional services offering support and assistance for medical imaging software users, enabling off-site expert help with MeVis applications.

6MeVisAP
CategoryApplication development platform
Description

Technical competence platform for application development and integration of MeVis software components into customer-specific medical imaging platforms.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Carestream offers Vue PACS, Clinical Collaboration Platform, and image-processing software serving hospitals and OEMs. Comparable to MeVis as an enterprise imaging software vendor with diagnostic visualization and clinical workflow capabilities, though with broader portfolio and focus on larger enterprise customers.

TypeEmerging player
Description

Lunit develops AI-powered medical image analysis, most notably Lunit INSIGHT for chest X-ray and mammography — directly competing with Veolity and MeVis's breast imaging capabilities. Comparable AI-first architecture with cloud-native deployment; smaller scale than MeVis but rapidly growing and well-funded.

TypeDirect peer
Description

Agfa HealthCare's Enterprise Imaging platform integrates RIS/PACS with advanced visualization and AI-driven diagnostic workflows for radiology. Comparable to MeVis in providing image-based diagnostic applications to hospitals and IT platform providers, with similar focus on workflow integration and clinical specialty modules.

TypeEmerging player
Description

Riverain Technologies offers ClearRead AI tools for chest CT and X-ray interpretation, including lung nodule and suppression technology. Comparable to Veolity in the lung cancer screening workflow niche; smaller scale and focused product line.

TypeEmerging player
Description

Optellum's Virtual Nodule Clinic and Lung Cancer Screening AI directly target the same clinical use case as MeVis's Veolity — lung nodule management and lung cancer risk prediction. Most direct emerging-AI competitor; FDA-cleared and CE-marked, with focused go-to-market in screening programmes.

TypeBroad incumbent
Description

GE HealthCare's Edison platform and AW workstation provide advanced visualization and AI applications for radiology including lung and liver analysis. Comparable to MeVis's enterprise imaging analytics offering; GE's CEO of MeVis (Marcus Kirchhoff) previously led GE Healthcare IT Central Europe sales, illustrating the close industry overlap.

TypeBroad incumbent
Description

Siemens Healthineers' syngo.via and AI-Rad Companion platforms provide post-processing and AI-assisted reading for CT, MR, and mammography — including lung, liver, and breast analysis. Comparable to MeVis's Veolity, MeVis Liver Suite, and breast imaging capabilities, but with broader modality coverage and embedded OEM relationships with Siemens imaging hardware.

TypeEmerging player
Description

Aidoc provides AI orchestration and triage solutions for radiology workflows across multiple modalities. Comparable to MeVis in providing AI-driven imaging analytics integrated into PACS/RIS workflows, but with a broader triage and acute-care focus versus MeVis's disease-specialized screening approach.

TypeBroad incumbent
Description

Philips offers enterprise imaging software including IntelliSpace Portal with lung cancer screening and AI-powered diagnostic modules. Directly comparable to MeVis in providing AI-driven analysis of CT/MR for lung and other disease areas, though as part of a much larger imaging and patient care portfolio serving global OEMs and providers.

TypeBroad incumbent
Description

FUJIFILM's Synapse PACS and AI-enabled radiology offerings target similar hospital and OEM customers as MeVis. Comparable in providing image visualization and analysis software across modalities, including lung and breast screening applications, though at substantially larger scale and as part of a broader imaging hardware portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MeVis Medical Solutions AG

Medical Imaging Softwaremevis.de

MeVis Medical Solutions AG is a Bremen-based, publicly traded medical imaging software company majority-owned by Varex Imaging Corporation, developing AI-assisted diagnostic software (Veolity lung cancer screening, MeVis Liver Suite, MeVisLab platform) licensed to medical device manufacturers and healthcare IT platform providers globally.

What MeVis Medical Solutions AG does

MeVis Medical Solutions AG is a Bremen, Germany-based, publicly traded (Frankfurt/XETRA, Berlin, Düsseldorf, Munich, Stuttgart; ticker M3V; ISIN DE000A0LBFE4) developer of image-based medical diagnostic software, founded in 1997 with technical roots in the 1992 CeVis initiative at the University of Bremen and the German Cancer Research Center (DKFZ). It has been listed since 2007 and is majority-owned by Varex Imaging Corporation (USA) through Varex Imaging Deutschland AG, with a control and profit transfer agreement in place subordinating the listing to the parent group. The company focuses on image-based early detection and diagnosis of breast, lung, and liver cancer as well as neurological diseases, supporting all major imaging modalities (MRI, digital mammography, CT, tomosynthesis, and ultrasound).

The product portfolio is built around the MeVisLab development platform and the MeVisAP application development platform. Application-layer products include Veolity (AI-powered lung cancer screening workflow for radiologists and national screening programs), MeVis Liver Suite (liver disease analysis), MeVis Online Academy (radiologist education via webinars and case collections), and MeVis Distant Services (MDS, remote support). The company operates an EN ISO 13485:2016-certified quality management system across EU, USA, Canada, Australia, and Taiwan under MDR, MDSAP, and related regimes.

Revenue is generated primarily through software licensing, development services, and ongoing support/maintenance sold via direct enterprise sales to medical device manufacturers and medical IT platform providers (RIS/PACS), with end users including radiologists and clinical institutions. Reported FY2024/2025 revenue was €16,061k against ~102 FTE, with an EBIT margin of 13% — down from €16,972k and 21% in FY2023/2024 — and a May 2026 forecast adjustment signaled continued near-term pressure. Marketing channels combine major industry congresses (RSNA, ECR, ESTI, RÖKO, ILTS, WCLC), the MeVis Online Academy, the corporate website, and LinkedIn/XING.

MeVis Medical Solutions AG firmographics

Firmographics
Name
MeVis Medical Solutions AG
Legal name
MeVis Medical Solutions AG
Website
https://mevis.de
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
51–100 employees
Short description
MeVis Medical Solutions AG is a Bremen-based, publicly traded medical imaging software company majority-owned by Varex Imaging Corporation, developing AI-assisted diagnostic software (Veolity lung cancer screening, MeVis Liver Suite, MeVisLab platform) licensed to medical device manufacturers and healthcare IT platform providers globally.
Ownership category
akta.pro rank

MeVis Medical Solutions AG industry classification

Industry
Product category
Medical Imaging Software
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Custom Computer Programming Services (541511)
SIC
Laboratory Analytical Instruments (3826)
akta.pro primary industry
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

  • Medical imaging software
  • Lung cancer screening
  • Liver diagnostics software
  • Radiology software solutions
  • Clinical image analysis

Where MeVis Medical Solutions AG is headquartered

Location

Headquarters

HQ city
Bremen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

MeVis Medical Solutions AG business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Software Licenses and Applications: MeVis develops and markets innovative software for analysis and evaluation of medical image data to manufacturers of medical products and providers of medical IT platforms. Revenue is generated through software licensing, development services, and ongoing support/maintenance.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

MeVis Medical Solutions AG product offering

Product offering

Core offering

MeVis Medical Solutions AG develops and markets specialized software for the analysis and evaluation of medical image data, supporting image-based early detection and diagnosis of breast, lung, and liver cancer as well as neurological diseases. The company sells its software products (including Veolity lung cancer screening, MeVis Liver Suite, and the MeVisLab platform) to manufacturers of medical devices and providers of medical IT platforms, with full-service support from product concept and application development through integration into customer platforms and ongoing quality assurance.

Product overview

MeVis Medical Solutions AG offers a portfolio of medical imaging software solutions comprising its core products Veolity (lung cancer screening with AI), MeVis Liver Suite (liver diagnostics), and MeVisLab (development platform). These are complemented by professional services including MeVis Online Academy (radiology education via webinars and case collections) and MeVis Distant Services (remote support). The company focuses on image-based early detection and diagnosis of epidemiologically significant diseases including breast cancer, lung cancer, liver cancer, and neurological diseases, supporting all major imaging modalities (MRI, digital mammography, CT, tomosynthesis, and ultrasound).

Differentiator

Problem solved

Functional benefit

Brands

  • MeVisLab: Software platform for medical image processing and visualization.
  • MeVis Online Academy
  • MeVis Distant Services (MDS)
  • MeVis Liver Suite
  • Veolity
  • MeVisAP

Products and services

  • Veolity Comprehensive lung cancer screening software solution that supports radiologists, screening centers, and national screening initiatives at every stage of the diagnostic workflow using AI-powered analysis for lung nodule management.
  • MeVis Liver Suite Specialized software suite for liver disease diagnosis and analysis that supports surgeons and medical professionals in liver-related imaging workflows.
  • MeVisLab Proprietary development environment and technical competence platform providing tools for visualizing and processing imaging data from medical to industrial applications, including a Path Tracer for photorealistic renderings.
  • MeVis Online Academy Webinar and case collection platform for radiologists offering educational content and professional development resources, including COVID-19 case collections.
  • MeVis Distant Services (MDS) Remote professional services offering support and assistance for medical imaging software users, enabling off-site expert help with MeVis applications.
  • MeVisAP Technical competence platform for application development and integration of MeVis software components into customer-specific medical imaging platforms.

Companies that use MeVis Medical Solutions AG

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

MeVis Medical Solutions AG technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

MeVis Medical Solutions AG partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

MeVis Medical Solutions AG competitors and assessment

Company assessment

Broad incumbents

  • Carestream Health: Carestream offers Vue PACS, Clinical Collaboration Platform, and image-processing software serving hospitals and OEMs. Comparable to MeVis as an enterprise imaging software vendor with diagnostic visualization and clinical workflow capabilities, though with broader portfolio and focus on larger enterprise customers.
  • GE HealthCare: GE HealthCare's Edison platform and AW workstation provide advanced visualization and AI applications for radiology including lung and liver analysis. Comparable to MeVis's enterprise imaging analytics offering; GE's CEO of MeVis (Marcus Kirchhoff) previously led GE Healthcare IT Central Europe sales, illustrating the close industry overlap.
  • Siemens Healthineers (syngo.via): Siemens Healthineers' syngo.via and AI-Rad Companion platforms provide post-processing and AI-assisted reading for CT, MR, and mammography — including lung, liver, and breast analysis. Comparable to MeVis's Veolity, MeVis Liver Suite, and breast imaging capabilities, but with broader modality coverage and embedded OEM relationships with Siemens imaging hardware.
  • Philips (IntelliSpace Portal): Philips offers enterprise imaging software including IntelliSpace Portal with lung cancer screening and AI-powered diagnostic modules. Directly comparable to MeVis in providing AI-driven analysis of CT/MR for lung and other disease areas, though as part of a much larger imaging and patient care portfolio serving global OEMs and providers.
  • FUJIFILM Healthcare (Synapse): FUJIFILM's Synapse PACS and AI-enabled radiology offerings target similar hospital and OEM customers as MeVis. Comparable in providing image visualization and analysis software across modalities, including lung and breast screening applications, though at substantially larger scale and as part of a broader imaging hardware portfolio.

Emerging players

  • Lunit: Lunit develops AI-powered medical image analysis, most notably Lunit INSIGHT for chest X-ray and mammography — directly competing with Veolity and MeVis's breast imaging capabilities. Comparable AI-first architecture with cloud-native deployment; smaller scale than MeVis but rapidly growing and well-funded.
  • Riverain Technologies (ClearRead): Riverain Technologies offers ClearRead AI tools for chest CT and X-ray interpretation, including lung nodule and suppression technology. Comparable to Veolity in the lung cancer screening workflow niche; smaller scale and focused product line.
  • Optellum: Optellum's Virtual Nodule Clinic and Lung Cancer Screening AI directly target the same clinical use case as MeVis's Veolity — lung nodule management and lung cancer risk prediction. Most direct emerging-AI competitor; FDA-cleared and CE-marked, with focused go-to-market in screening programmes.
  • Aidoc: Aidoc provides AI orchestration and triage solutions for radiology workflows across multiple modalities. Comparable to MeVis in providing AI-driven imaging analytics integrated into PACS/RIS workflows, but with a broader triage and acute-care focus versus MeVis's disease-specialized screening approach.

Direct peers

  • Agfa HealthCare (Enterprise Imaging): Agfa HealthCare's Enterprise Imaging platform integrates RIS/PACS with advanced visualization and AI-driven diagnostic workflows for radiology. Comparable to MeVis in providing image-based diagnostic applications to hospitals and IT platform providers, with similar focus on workflow integration and clinical specialty modules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

MeVis Medical Solutions AG social profiles

Digital presence

MeVis Medical Solutions AG compliance and trust

Trust signal

Compliance3 records

MeVis Medical Solutions AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MeVis Medical Solutions AG leadership team

Management profile

Number of profiles

Profiles4 records

MeVis Medical Solutions AG funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MeVis Medical Solutions AG M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MeVis Medical Solutions AG

What does MeVis Medical Solutions AG do?

MeVis Medical Solutions AG develops and markets specialized software for the analysis and evaluation of medical image data, supporting image-based early detection and diagnosis of breast, lung, and liver cancer as well as neurological diseases. The company sells its software products (including Veolity lung cancer screening, MeVis Liver Suite, and the MeVisLab platform) to manufacturers of medical devices and providers of medical IT platforms, with full-service support from product concept and application development through integration into customer platforms and ongoing quality assurance.

Is MeVis Medical Solutions AG a public or private company?

MeVis Medical Solutions AG is a public company. It is classified as public and is currently operating.

When was MeVis Medical Solutions AG founded?

MeVis Medical Solutions AG was founded in 1997. It employs 51 to 100 people.

Where is MeVis Medical Solutions AG based?

MeVis Medical Solutions AG is headquartered in Bremen, Germany, in the Europe region.

How does MeVis Medical Solutions AG make money?

One revenue line is on record: software Licenses and Applications.

Who are MeVis Medical Solutions AG's main competitors?

Broad incumbents on record are Carestream Health, GE HealthCare, Siemens Healthineers (syngo.via), Philips (IntelliSpace Portal) and FUJIFILM Healthcare (Synapse). Emerging players are Lunit, Riverain Technologies (ClearRead), Optellum and Aidoc. Agfa HealthCare (Enterprise Imaging) is listed as a direct peer.

Does MeVis Medical Solutions AG have an API?

No public API is recorded for MeVis Medical Solutions AG.

What industry is MeVis Medical Solutions AG in?

MeVis Medical Solutions AG's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 3345 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deEQS-Adhoc: MeVis Medical Solutions AG: Prognoseanpassung für das Geschäftsjahr 2025/2026MeVis Medical Solutions AG revised its 2025/2026 forecast downward, expecting revenue of €15.0–15.5 million versus €16.5–17.0 million previously. The company anticipates an EBIT loss of €1.0–1.5 million, citing weaker mammography demand from Hologic and slow lung cancer screening implementation in Germany.GlobeNewswireDGAP-Adhoc: MeVis Medical Solutions AG: Raising forecast for the current fiscal yearMeVis Medical Solutions AG raised its forecast for the short fiscal year 2016 (Jan 1–Sep 30) to revenues of EUR 11.5–12.0 million and EBIT of EUR 3.5–4.0 million, citing strong Digital Mammography performance. The company's fiscal year now runs Oct 1 to Sep 30, with the current period being a short fiscal year.GlobeNewswireDGAP-News: MeVis Medical Solutions AG: MeVis Q1 2016:MeVis Medical Solutions reported Q1 2016 revenue of EUR 3.876 million, up 14% year-on-year, with EBIT of EUR 1.183 million and a 31% margin. Maintenance revenues rose 27% to EUR 1.889 million, while the financial result declined to EUR -859k due to exchange-rate effects.GlobeNewswireDGAP-News: MeVis Medical Solutions AG: MeVis publishes figures for fiscal year 2015 and guidance for 2016MeVis Medical Solutions AG reported fiscal 2015 revenues of EUR 16.0m, up 22% year on year, with EPS of EUR 3.76. The company guided 2016 revenues to EUR 14.5m–15.0m, citing a strong Hologic dependency. It expects a significant decline in Hologic business by end of 2017.GlobeNewswireDGAP-News: MeVis Medical Solutions AG: MeVis Q3 2015: Previous trend continuedMeVis Medical Solutions reported Q3 2015 sales of EUR 4.8m, up 33% year-on-year, driven by a strong US dollar. EBIT rose to EUR 3.6m (30% margin), but net profit fell to EUR 3.0m cumulatively. The company also finalized a domination and profit-and-loss transfer agreement.GlobeNewswireDGAP-News: MeVis Medical Solutions AG: Domination and profit and loss transfer agreement registered with the Commercial RegisterMeVis Medical Solutions AG announced that its domination and profit and loss transfer agreement with VMS Deutschland Holdings GmbH was registered with the Bremen Commercial Register on October 20, 2015. The agreement requires VMS to buy MeVis shares at EUR 19.77 per share, with optional annual compensation of EUR 1.13 gross per share.GlobeNewswireDGAP-News: MeVis Medical Solutions AG: Approval of the domination and profit and loss transfer agreement with the VMS Deutschland Holdings GmbHMeVis Medical Solutions AG's extraordinary general meeting approved a domination and profit and loss transfer agreement with VMS Deutschland Holdings GmbH, supported by 98.40% of shareholders. The agreement requires commercial register registration and includes minority shareholder protections, such as annual compensation and share transfer options.GlobeNewswireDGAP-Adhoc: MeVis Medical Solutions AG: Raising forecast for the current fiscal yearMeVis Medical Solutions AG raised its 2015 forecast, citing positive digital mammography development. It now expects revenues of EUR 14.5-15.0 million and EBIT of EUR 3.5-4.0 million, up from previous estimates. Liquidity is also projected to rise to EUR 23-24 million by year-end.GlobeNewswireDGAP-News: MeVis Q2 2015: Revenues benefit from strong US dollarMeVis Medical Solutions reported Q2 2015 sales of EUR 3.73m, up 15% year-on-year, driven by a strong US dollar. EBIT fell to EUR 1.627m (23% margin) and net profit to EUR 1.268m, while liquidity rose to EUR 21.6m.GlobeNewswireDGAP-Adhoc: MeVis Medical Solutions AG: Raising forecast for the current fiscal yearMeVis Medical Solutions AG raised its 2015 forecast, citing positive digital mammography growth and dollar strength. It expects revenues to rise to EUR 14.0-14.5 million and EBIT to EUR 3.0-3.5 million, up from prior forecasts.